Surgery Partners, Inc.SGRYNASDAQ
Loading
Surgery Partners operates 180+ surgical facilities across the United States, primarily ambulatory surgery centers (ASCs) and surgical hospitals focused on short-stay procedures. The company partners with physicians and health systems to deliver outpatient surgical care at lower costs than traditional hospital settings, benefiting from the structural shift toward value-based care and site-of-service migration. Revenue growth is driven by same-facility case volume increases, facility acquisitions, and payor mix optimization toward higher-reimbursement commercial insurance.
Surgery Partners generates revenue through facility fees charged to payors (commercial insurance, Medicare, Medicaid) for surgical procedures performed at its centers. The ASC model delivers 40-60% cost savings versus hospital outpatient departments, creating pricing power with commercial payors while maintaining attractive margins. Profitability depends on case volume throughput, payor mix (commercial insurance pays 3-4x Medicare rates), and operational efficiency across the facility network. The company partners with physician groups who refer cases and often hold minority equity stakes, aligning incentives. Growth comes from organic case volume expansion (2-4% annually), de novo facility development, acquisitions of independent ASCs, and converting hospital outpatient procedures to lower-cost ASC settings.
Same-facility case volume growth rates (organic demand indicator, typically 2-5% quarterly growth)
Acquisition pipeline activity and integration execution (10-20 facilities annually at 6-8x EBITDA multiples)
Commercial payor mix percentage (commercial cases generate 200-300 bps higher margins than Medicare)
Surgical facility utilization rates and revenue per case trends (pricing power and efficiency metrics)
Debt refinancing activity and leverage ratio trajectory (currently 2.2x D/E, target path toward 1.5x)
Medicare reimbursement rate pressure: CMS rate updates (typically 0-2% annually) lag cost inflation, compressing margins on 25-30% of case volume. Potential legislative changes to site-neutral payment policies could eliminate ASC cost advantages.
Regulatory scope-of-practice expansion: State-level scope expansions allowing procedures in physician offices or imaging centers could fragment case volumes. Certificate-of-Need (CON) laws in 35 states create barriers but also protect existing facilities from competition.
Physician alignment risks: ASC model depends on physician partnerships and referral relationships. Employed physician models at large health systems could redirect cases to hospital-owned facilities, reducing independent ASC volumes.
Health system vertical integration: Large hospital systems (HCA, Tenet, UHS) are acquiring ASCs and building ambulatory networks, leveraging scale advantages and payor contracting power. United Surgical Partners (Tenet subsidiary) and HCA's ambulatory division are primary competitors.
Private equity consolidation: PE-backed platforms (SCA Health, Envision) are aggregating ASCs at premium valuations, intensifying acquisition competition and compressing returns on new facility purchases.
High leverage profile: 2.24x debt-to-equity ratio with estimated $1.4-1.6B total debt creates refinancing risk and limits financial flexibility. Negative net margin (-5.4%) and ROE (-9.8%) indicate the capital structure is pressuring equity returns.
Working capital management: Healthcare receivables create 45-60 day collection cycles. Payor disputes or claim denials can extend DSO and pressure liquidity. Current ratio of 1.88x provides moderate cushion but requires active management.
moderate - Elective surgical procedures (60-70% of case mix) are economically sensitive as patients defer non-urgent orthopedic, ophthalmology, and cosmetic procedures during recessions or when facing financial stress. However, essential procedures (colonoscopies, cataract surgeries, pain management) provide 30-40% revenue stability. Commercial insurance enrollment correlates with employment levels, affecting payor mix quality. Historical data shows 5-10% case volume declines during recessions, partially offset by Medicare volume stability.
Rising interest rates increase borrowing costs on the company's $1.4-1.6B debt load (estimated based on 2.24x D/E ratio), with floating-rate exposure on revolving credit facilities impacting interest expense by $3-5M per 100bps rate increase. Higher rates also pressure acquisition economics by increasing the cost of capital for leveraged facility purchases. Valuation multiples compress as healthcare services stocks trade at wider spreads to risk-free rates. However, ASC business model generates consistent cash flow (10% FCF yield), providing some defensive characteristics.
Moderate credit sensitivity. Tightening credit conditions reduce access to acquisition financing and increase refinancing costs on the leveraged balance sheet. However, the company's essential healthcare services generate predictable cash flows with limited credit risk to end customers (payors are primarily large insurance companies and government programs). Physician partner relationships and facility-level cash generation provide operational resilience during credit stress.
value - The stock trades at 0.6x P/S and 7.0x EV/EBITDA, well below healthcare services peers (typically 10-12x EBITDA), suggesting deep value opportunity if operational turnaround succeeds. The 10.1% FCF yield attracts value investors focused on cash generation despite negative reported earnings (driven by non-cash charges). However, negative net margin and high leverage create execution risk, requiring conviction in management's deleveraging and margin expansion strategy. Recent 38% one-year decline has created contrarian entry point for distressed/special situations investors.
high - Small-cap healthcare services stock with leveraged balance sheet and negative profitability exhibits elevated volatility. The 38% one-year decline and 29% six-month drawdown demonstrate significant price swings. Quarterly earnings volatility driven by acquisition timing, integration costs, and reimbursement changes creates trading opportunities but requires risk tolerance. Beta likely 1.3-1.5x relative to broader market.